As of Friday close, IDEAYA Biosciences Inc.’s (NASDAQ:IDYA) stock was up $1.45, moving up 5.83 percent to $26.31. The average number of shares traded per day over the past five days has been 547,920 shares. 3 times new highs have been achieved over the past 5 days, with a $1.20 gain in that time frame. In the last twenty days, the average volume was 509,885, while in the previous 50 days, it was 504,510.
Since last month, IDYA stock rose 20.25%. Shares of the company fell to $20.90 on 07/27/23, the lowest level in the past month. A 52-week high of $26.50 was reached on 08/16/23 after having rallying from a 52-week low of $9.00. Since the beginning of this year, IDYA’s stock price has risen by 44.80% or $8.14, and marked a new high 17 times. However, the stock has declined by -0.72% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
IDYA stock investors should be aware that IDEAYA Biosciences Inc. (IDYA) stock had its last reported insider trading activity 1 day ago on Aug 18. Stone Paul A., the Chief Financial Officer of the company, disposed of 3,822 shares for $26.38 on Aug 18. It resulted in a $100,820 divestment by the insider. Stone Paul A. sold 200 shares at an average price of $26.43 on Aug 16. The insider now owns 19,103 shares following the transaction. On Aug 09, Chief Legal Officer Throne Jason sold 5,000 shares at $25.09 apiece. The transaction was valued at $125,430.
Valuation Metrics
The stock’s beta is 0.75. Besides these, the trailing price-to-sales (P/S) ratio of 32.23, the price-to-book (PB) ratio of 2.95.
Financial Health
In the three months ended June 29, IDEAYA Biosciences Inc.’s quick ratio stood at 19.80, while its current ratio was 19.80, showing that the company is able to pay off its debt. Based on annual data, IDYA earned $113.43 million in gross profit and brought in $50.93 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -17.90%. Return on equity (ROE) for the past 12 months was -19.10%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. IDYA’s revenue fell -65.25% to $7.88 million during the quarter, while net income inched up to $3.54 million. While analysts expected IDEAYA Biosciences Inc. to report -$0.56 quarterly earnings, the actual figure was -$0.5 per share, beating the consensus estimate by 10.70%. During the quarter, the company generated -$34.64 million in EBITDA. The liabilities of IDEAYA Biosciences Inc. were 25.95 million at the end of its most recent quarter ended June 29, and its total debt was $2.57 million. The value of shareholders’ equity is $57.56 million.
Technical Picture
This quick technical analysis looks at IDEAYA Biosciences Inc.’s (IDYA) price momentum. With a historical volatility rate of 73.10%, the RSI 9-day stood at 71.57% on 18 August.
With respect to its five-day moving average, the current IDEAYA Biosciences Inc. price is up by +4.78% percent or $1.20. At present, IDYA shares trade +21.69% above its 20-day simple moving average and +91.48% percent above its 100-day simple moving average. However, the stock is currently trading approximately +3.58% above its SMA50 and +55.77% above its SMA200.
Stochastic coefficient K was 80.83% and Stochastic coefficient D was 78.96%, while ATR was 1.30. Given the Stochastic reading of 96.40% for the 14-day period, the RSI (14) reading has been calculated as 67.98%. As of today, the MACD Oscillator reading stands at 0.60, while the 14-day reading stands at 1.66.
Analyst Ratings
SVB Securities launched its rating on IDEAYA Biosciences Inc. (NASDAQ: IDYA) to an Outperform in a note to investors on August 08, 2023. IDEAYA Biosciences Inc. (IDYA) has been rated Buy by analysts. According to 0 brokerage firms, IDYA is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate IDEAYA Biosciences Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $34.00, the current consensus forecast for the stock is $30.00 – $42.00. Based on these forecasts, analysts predict IDEAYA Biosciences Inc. (IDYA) will achieve an average price target of $35.08.
